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The  purpose  of  this  study  was  to simultaneously  improve  the  solubility  and  stability  of dihydroartemisinin
(DHA)  in  aqueous  solutions  by  a ternary  cyclodextrin  system  comprised  of  DHA, hydroxypropyl-ˇ-
cyclodextrin (HP-ˇ-CD)  and  a third  auxiliary  substance.  Solubility  and  phase  solubility  studies  were
carried  out  to evaluate  the solubilizing  efﬁciency  of  HP-ˇ-CD  in  association  with  various  auxiliary  sub-
stances.  Then,  the solid  binary  (DHA–HP-ˇ-CD  or DHA–lecithin)  and  ternary  systems  were  prepared  and
characterized  by Fourier  transform  infrared  (FT-IR),  differential  scanning  calorimetry  (DSC)  and  power
X-ray  diffraction  (PXRD).  The  effect  of  the  ternary  system  on  the  solubility,  dissolution  and  stability  of
DHA  in  aqueous  solutions  was  also  investigated.  As a  result,  the  soybean  lecithin  was  found  to  be the  most
promising  third  component  in  terms  of solubility  enhancement.  For  the  solid  characterization,  the disap-
pearance  of  the drug  crystallinity  indicated  the  formation  of  new  solid  phases,  implicating  the  formation
of  the  ternary  system.  The  dissolution  rate  of  the  solid  ternary  system  was  much  faster  than  that  of  the
drug alone  and  binary  systems.  Importantly,  compared  with  binary  systems,  the  ternary  system  showed
a signiﬁcant  improvement  in  the  stability  of  DHA  in Hank’s  balanced  salt  solutions  (pH  7.4). The  solubility
and  stability  of  DHA  in aqueous  solutions  were  simultaneously  enhanced  by the ternary  system,  which
might  be  attributed  to  the  possible  formation  of  a ternary  complex.  For  the  ternary  interactions,  results  of
molecular  docking  studies  further  indicated  that  the  lecithin  covered  the  top  of  the  wide  rim of  HP-ˇ-CD
and  surrounded  around  the peroxide  bridging  of  DHA, providing  the  possibility  for the  ternary  complex
formation.  In summary,  the  ternary  system  prepared  in our  study,  with  simultaneous  enhancement  of
DHA solubility  and  stability  in aqueous  solutions,  might  have  an important  pharmaceutical  potential  in
the  development  of a better  oral  formulation  of DHA.
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1. Introduction
The combination of dihydroartemisinin (DHA)-piperaquine is
recommended to cure plasmodium infections by World Health
Organization (WHO) in 2010. However, an increased treatment fail-
ure with DHA has been reported in the western Cambodia from
8.1% to 27.6% in 2010 [1]. The major reason is the Plasmodium
resistance to antimalarial medicines, which makes the transmis-
sion of malaria gain momentum in turn and brings new challenges
to the malaria prevention. The long term use of drugs with relative
low solubility, stability and bioavailability is possibly a negatively
Open access under CC BY-NC-ND license.important factor to malaria drug resistance. The use of effective
drugs with relative high solubility, stability and bioavailability
will be of great beneﬁt to reduce the incidence of malaria drug
resistance.
D license.
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Among artemisinin derivatives, DHA provides improved anti-
alarial potency in vitro and in vivo compared to other artemisinin
nalogues. However, the aqueous solubility of DHA is very low
ue to the glucopyranose rings in its chemical structure [2,3]. It
ontains peroxide bridging over the seven-membered ring, which
s known to be rather unstable. The hemiacetal functional group,
hich is more susceptible to acidic situations and moisture, is
nother contributor to its low stability [4,5]. DHA is also physically
nstable due to the conversion of the lactone carbonyl group at C-10
Fig. 1).
It is reported that artemisinin products in the market have
ardly met  the criteria of WHO, especially in Africa. The active phar-
aceutical ingredient content is below the criterion of 90% at the
nd of shelf life [2]. In addition, the huge demand of artemisinins has
reated a global shortage of artemisinins. Therefore, it is urgently
eeded to develop DHA products with high solubility, stability and
ioavailability. Several studies have been carried out to enhance the
olubility and stability of DHA by preparing solid dispersions [6],
anosuspensions [7], micronization with supercritical solutions
8], and cyclodextrin complexes [9,10]. Among them, cyclodextrin
nclusion is one of the most efﬁcient ways to improve the solu-
ility and stability of DHA. It has been reported that the aqueous
olubility of DHA increased 77 folds after complexation with HP-
-CD. The hydrolysis rate constant of DHA in solid complexes of
P-ˇ-CD (275.1 mM)  decreased 29 folds compared with DHA alone
t 50 ◦C after 3 months [5], and the degradation rate constant of
HA in aqueous solutions decreased approximately 10 folds in the
resence of HP-ˇ-CD (57 mM)  at 60 ◦C [11].
However, due to the relatively high molecular weight of HP-ˇ-
D, a large amount of cyclodextrins used in the formulation limits
ts application into a convenient and cost-effective dosage form.
oreover, high dose of cyclodextrins may  lead to potential toxicity
nd other related side effects, which also impedes its application
12]. It is of importance to improve the complexation of DHA and
yclodextrins. Recently, it is reported that ternary system with
rug, cyclodextrin and the third auxiliary substance can reduce
he dose of cyclodextrins and increase the complexation efﬁciency
Table 1) [13–28].
To our literature research, there is no report available about the
ernary system of DHA with HP-ˇ-CD and auxiliary substances up
o now. In this study, the simultaneous enhancement of solubil-
ty and stability of DHA through ternary system was investigated.
he auxiliary substance added in the ternary system was screened
hrough solubility studies. Then, the binary and the ternary systems
or DHA constituted with HP-ˇ-CD and the optimal auxiliary sub-
tance were prepared by the solvent evaporation method. Finally,
he properties of DHA in the binary system, the ternary system
nd their physical mixtures were characterized by FT-IR, DSC and
XRD techniques in solid state, whilst their solubility, stability and
issolution behaviours in aqueous state were evaluated. Finally,ydroartemisinin.
combined with the solid state characterization, the possible molec-
ular formation mechanism of the ternary complex was  investigated
by the molecular docking study.
2. Experimental methods
2.1. Materials
Dihydroartemisinin (DHA, 99% purity) was  obtained from
Chongqing Huali Wulingshan Medicine Co., Ltd. (Chongqing,
China). 2-Hydroxypropyl-ˇ-cyclodextrin (HP-ˇ-CD, degree of
substitution = 4.5) was  obtained from China Shijiazhuang Phar-
maceutical Group Co., Ltd. (Shijiazhuang, Hebei, China). Soybean
lecithin (phosphatidyl choline, 94% purity) was supplied by
Lipoid GmbH (Ludwigshafen, Germany). Polyethylene glycol 4000
(PEG4000), polyethylene glycol 6000 (PEG6000), polyvinyl pyr-
rolidone K30 (PVP) and lactose were obtained from Sinopharm
Chemical Reagent Co., Ltd (Shanghai, China). Polyethylenglycol
660-12-hydroxystearate (Solutol HS15) was  procured from BASF
(Germany). Lauroyl polyoxylglycerides (Gelucire 44/14) was  pur-
chased from Gattefosse (France). Hydroxypropyl methylcellulose
(HPMC K4M) was  obtained from Dow Chemical Company (USA).
Acetonitrile and methanol were high performance liquid chro-
matography grade from Merck Co., Ltd. (Germany). Hank’s balanced
salts were purchased from Sigma-Aldrich Co. LLC. (USA). Water was
prepared by ultra pure water system (Milli-Q). Other reagents were
of analytical grade.
2.2. Methods
2.2.1. HPLC analysis
Quantitative analysis of DHA was  performed using HPLC method
listed in Chinese Pharmacopoeia (2010 edition). The HPLC instru-
ments consisted of a binary pump, G1311C; autosampler, G1329B;
and a diode-array detector G4212B (Agilent, Palo Alto, USA). The
separation was achieved on a Diamonsil C18 analytical column
(150 × 4.6 mm ID, 5 m,  Dikma, Beijing, China) equipped with an
Easyguard ii C18 guard column (Dikma, Beijing, China) maintained
at 20 ◦C. The mobile phase consisted of acetonitrile: ultra pure
water (65:35, v/v) and the ﬂow rate was  set to 1 mL  min−1. The
detection wavelength of the detector was set to 210 nm.
2.2.2. Stability studies
The stability tests of pure DHA in water or Hank’s balanced
salt solutions were carried out at 37 ◦C indicating the dissolution
test temperature. The Hank’s balanced salt solution was prepared
with 8.00 g L−1 NaCl, 0.40 g L−1 KCl, 0.35 g L−1 NaHCO3, 0.06 g L−1
KH2PO4, 0.05 g L−1 Na2HPO4, 0.19 g L−1 CaCl2·2H2O, 0.09 g L−1
MgSO4, and 1.00 g L−1 glucose and the pH values were adjusted
to 6.8, 7.0, 7.2 and 7.4 with NaHCO3 (3.8 mM,  pH11.2) solution.
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For the stability tests in water and in Hank’s balanced salt solu-
tions (pH6.8, 7.0, 7.2, 7.4), DHA solution with the concentration of
100 g mL−1 was ﬁrstly put into 10 mL  test tubes with plugs. Then,
aliquots of 0.5 mL were taken out at intervals of 1 h at 37 ◦C in 6 h.
The concentration of DHA was measured by HPLC. Each test was
performed in triplicate.
Since the degradation of DHA followed ﬁrst-order kinetics in
the presence of HP-ˇ-CD and lecithin, the apparent degradation
rate constants (k) used to evaluate the stability of DHA were calcu-
lated from the slope of the degradation diagrams according to the
following Eq. (1) [29].
ln[C] = ln[C0] − kt (C /= C0) (1)
where [C0] was the initial concentration of DHA, [C] was  the con-
centration of DHA at time t, and k was the slope of the ﬁtted linear
regression for the ﬁrst order reaction.
2.2.3. Solubility and phase solubility studies
Solubility studies were carried out to screen the auxiliary sub-
stances. An excess amount of DHA was  added to 0.5% (3.6 mM,
w/v) HP-ˇ-CD solutions containing concentrations of auxiliary sub-
stances (0–0.2%, w/v). The mixtures were shaken in a thermostatic
oscillator (THZ-D, Suzhou Pei Ying Experimental Equipment Co.,
Ltd., Jiangsu, China) at 25 ◦C for 72 h to achieve the equilibrium.
Appropriate aliquots of the mixture were then withdrawn and
ﬁltered with a polyvinylidene ﬂuoride syringe-ﬁlter (pore size
0.22 m),  and the concentrations of DHA in the ﬁltrates were ana-
lyzed by HPLC.
The phase solubility studies were carried out according to the
Higuchi-Connors procedure [30]. An excess amount of DHA was
added to 5 mL  aqueous solutions containing various concentrations
of HP-ˇ-CD (0–18 mM)  and lecithin (0%, 0.5% and 1.0%, w/v). The
mixtures were shaken in the thermostatic oscillator at 25 ◦C for
72 h to achieve the equilibrium. Appropriate aliquots of the mixture
were then withdrawn and ﬁltered with a polyvinylidene ﬂuoride
syringe-ﬁlter (pore size 0.22 m),  and the total concentrations of
DHA in the ﬁltrates were analyzed by HPLC.
Phase solubility diagrams were obtained by plotting the molar
concentration of DHA versus the molar concentration of HP-ˇ-CD.
For the 1:1 drug/HP-ˇ-CD complex, the complexation efﬁciency
and the apparent stability constant could be estimated from the
slope of the phase solubility diagram (Eqs. (2) and (3)) [31].
CE = slope
1 − slope (2)
K1:1 =
slope
[S0(1 − slope)]
(3)
where CE was  the complexation efﬁciency, slope was  the slope of
the phase solubility diagram, K1:1 was the apparent stability con-
stant and S0 was the equilibrium solubility of DHA in water in the
absence of HP-ˇ-CD and the lecithin.
2.2.4. Preparations of the binary system and the ternary system
The binary system and the ternary system were pre-
pared by the solvent evaporation method as follows. For
the preparation of DHA–HP-ˇ-CD binary system, DHA
(molecular weight = 284 g moL−1) and HP-ˇ-CD (molecular
weight = 1396 g moL−1) were dissolved in anhydrous methanol
with a mass ratio of 1:5 (w/w) and stirred at 800 rpm for 1 h to
achieve equilibrium. The solution was evaporated using rotary
evaporator (IKA, Germany) under reduced pressure to remove
the organic solvent at 30 ◦C. The DHA–HP-ˇ-CD binary residues
were dried in vacuum at 30 ◦C over-night. The preparation
of DHA–lecithin binary system (1:5, w/w) was  the same to
DHA–HP-ˇ-CD binary system.
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For the ternary system preparation, after the equilibrium
eached, a weighted amount of lecithin equal to the amount of HP-
-CD was added in the mixture and agitated until the suspension
as transparent. The mass ratio of DHA: HP-ˇ-CD: lecithin was
:5:5 (w/w/w). The solution was evaporated under reduced pres-
ure to remove the organic solvent at 30 ◦C. The ternary residues
ere dried in vacuum at 30 ◦C over-night.
Appropriate amounts of the dried residues obtained from above
reparations of the binary system and the ternary system were
dded in water and the suspensions were ﬁltered through a
.22 m polyvinylidene ﬂuoride membrane to remove the insol-
ble DHA. The ﬁltrates were lyophilized to obtain the ﬁnished
roducts of the binary system and the ternary system. The drug
oading (DL) percentages of the binary system and the ternary sys-
em were determined and calculated according to Eq. (4).
L =
(
WDHA
W0
)
× 100% (4)
here WDHA is the weight of DHA in the lyophilized powders of
he binary system and the ternary system and W0 is the weight
f the lyophilized powders of the binary system and the ternary
ystem. Both the lyophilized binary system and the lyophilized
ernary system were further used to perform the solid properties
haracterizations. The physical mixtures in equal proportions to the
ompositions of the lyophilized binary system and the lyophilized
ernary system were prepared as reference for the characterization.
.2.5. Characterization of the binary system and the ternary
ystem in solid state
The properties of DHA, HP-ˇ-CD, lecithin, DHA–HP-ˇ-CD phys-
cal mixture, DHA–HP-ˇ-CD binary system, DHA–lecithin physical
ixture, DHA–lecithin binary system, ternary physical mixture and
HA–HP-ˇ-CD–lecithin ternary system in solid state were charac-
erized by FT-IR, DSC and PXRD.
.2.5.1. Fourier transform infrared spectroscopy. The FT-IR spec-
roscopy was acquired with a Nicolette 6700 FT-IR apparatus. The
amples were mixed with KBr and a tablet was prepared and the FT-
R spectroscopy was detected at 400–4000 cm−1. The instrument
as operated under dry air purge, and the scans were collected at
he scanning speed of 2 mm s−1 with the resolution of 4 cm−1. The
umber of scans was adjusted automatically as a function of sample
oncentration in the disc.
.2.5.2. Differential scanning calorimetry. The DSC thermograms
ere recorded using a differential scanning calorimeter (DSC 822,
ettler Toledo, Switzerland). About 2.0 mg  of each sample was
eated in a pierced aluminium pan from 50 to 250 ◦C at a heating
ate of 10 ◦C min−1. Thermal data analysis of the DSC thermograms
as conducted using the Mettler Toledo STAR system software.
.2.5.3. Powder X-ray diffraction. Diffraction patterns were
etected with a Bruker D8 Advance diffractometer at ambient
emperature. The samples were irradiated with monochromatized
u K radiation and analyzed at a 2 theta angle range 3–40◦. The
attern was collected with a tube voltage of 40 kV and a tube
urrent of 40 mA  in step scan mode (8◦ min−1).
.2.6. Evaluation of the ternary system in aqueous state
.2.6.1. In vitro dissolution studies. Dissolution studies were per-
ormed in triplicate according to the paddle method in Chinese
harmacopoeia (2010 edition) at 37 ◦C. Samples containing 10 mg
f DHA or its equivalent as a binary system or a ternary system were
dded to 250 mL  of water and stirred at 100 rpm. At time points of
, 10, 15, 30, 60, 90, 120, 180 and 360 min, 2 mL  of samples were
ithdrawn and replaced with an equal volume of fresh medium.Biomedical Analysis 83 (2013) 141– 148
The samples were ﬁltered through 0.22 m polyvinylidene ﬂuoride
membrane and analyzed by HPLC method at 210 nm.
2.2.6.2. Stability analysis. For stability studies, the solutions of the
binary system or the ternary system containing 100 g mL−1 of
DHA were prepared with Hank’s balanced salt solution (pH 7.4).
The triplicate samples were incubated at 37 ◦C in water bath for 4 h.
The stabilities were tested by the same method deﬁned in Section
2.2.2.
3. Results and discussion
3.1. Method validation for the quantiﬁcation of DHA
Two isomers of DHA, namely, - and -epimers, were separated
by HPLC determination. Because the two  isomers of DHA were apt
to transform into each other, the reference materials of the two
epimers were not available. Thus, the peak area of DHA was esti-
mated by the sum of -epimer and -epimer.
3.1.1. Speciﬁcity
The speciﬁcity of the method was determined by comparing test
results obtained from analysis of sample solution containing aux-
iliary substances and DHA with that obtained from DHA. In the
presence of HP-ˇ-CD and auxiliary substances, it was found that
there was no signiﬁcant change in peak shape and retention time
of DHA.
3.1.2. Linearity
The limit of detection (LOD) and the limit of quantitation (LOQ)
of DHA were 0.5 g mL−1 (S/N > 3) and 1.0 g mL−1 (S/N > 10). The
calibration curve was linear over the concentrations of 1.0, 2.0, 5.0,
10.0, 20.0, 50.0, 100.0, 200.0, 500.0 g mL−1 (R2 = 0.9999).
3.1.3. Recovery
The recovery of the method was  evaluated at the DHA concen-
trations of 100, 250 and 500 g mL−1 in the presence of HP-ˇ-CD
(0.5%, w/v) and the other auxiliary substances (0.2%, w/v). The
results showed that the recoveries of samples at three concentra-
tions of DHA for all of the auxiliary substances were 98.2–101.9%
(8 groups, for each group n = 9). The results indicated that there
were no signiﬁcant inﬂuence of ternary compounds used (HP-ˇ-
CD, polymers and lecithin) on the quantiﬁcation of DHA and the
method was accurate and precise.
3.2. Solubility and phase solubility studies
DHA was slightly soluble in water (134.8 g mL−1, 25 ◦C). In the
presence of 0.5% (w/v) HP-ˇ-CD, the solubility of DHA increased to
302.7 g mL−1. Except soybean lecithin showed certain improve-
ment of the solubility of DHA in the presence of HP-ˇ-CD, whilst
the addition of the other selected third auxiliary substances did
not obviously improve the solubility of DHA compared with the
HP-ˇ-CD solution (0.5%, w/v) (Table 2).
As shown in Table 2, the solutions containing 0.5% (w/v) HP-
ˇ-CD and soybean lecithin showed some enhancement of the
solubility of DHA. The system containing 0.2% (w/v) lecithin
and 0.5% (w/v) HP-ˇ-CD exhibited the highest solubility of DHA
(413.4 g mL−1). However, for solutions with other auxiliary sub-
stances, the solubility of DHA increased slightly, even if increasing
the concentrations of the auxiliary substances. For solution contain-
ing HPMC, the solubility of DHA decreased about 15% compared
to the DHA–HP-ˇ-CD binary system. Furthermore, the auxiliary
substances like PEG4000, PEG6000, PVP K30, lactose and Solutol
HS15 had slight effects on the solubility improvement of DHA in
the DHA–HP-ˇ-CD binary system. The favourable effect of lecithin
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Table  2
Solubility of DHAa (g mL−1) in the presence of 0.5% HP-ˇ-CD and the third auxiliary
substances (mean ± SD).
The third auxiliary substance Concentration of auxiliary substance (w/v)
0.05% 0.10% 0.20%
Soybean lecithin 319.0 ± 5.8 348.4 ± 9.8 413.4 ± 16.0
PEG4000 304.7 ± 1.7 301.3 ± 3.2 305.2 ± 8.7
PEG6000 317.7 ± 4.3 323.4 ± 9.1 321.2 ± 6.1
PVP K30 314.1 ± 5.2 323.0 ± 4.3 308.0 ± 10.2
Lactose 300.9 ± 1.0 307.8 ± 2.9 313.4 ± 5.0
Solutol HS15 303.5 ± 4.1 305.5 ± 4.3 303.5 ± 0.4
Gelucire 44/14 291.5 ± 5.6 265.1 ± 3.6 258.9 ± 7.3
HPMC 259.5 ± 8.5 266.0 ± 11.3 248.7 ± 9.9
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Fig. 2. FTIR spectra of pure DHA (A), HP-ˇ-CD (B), lecithin (C), DHA–HP-ˇ-CD phys-
exothermic peaks of DHA obviously disappeared in the binary sys-a The solubility of DHA in water was 134.8 ± 0.3 g mL−1, and the solubility of
HA in the presence of 0.5% (w/v) HP-ˇ-CD was 302.7 ± 5.1 g mL−1.
n the solubility improvement of DHA might be ascribed to its
mphiphilic property.
The phase solubility study was also performed at 25 ◦C in aque-
us solutions with different concentrations of HP-ˇ-CD in the
resence of lecithin (0%, 0.5% and 1.0% (w/v)). The phase solubil-
ty diagram displayed an AL type, showing a linear increase of drug
olubility. The slopes in all cases were less than unity, indicating
he formation of 1:1 binary and ternary system. It was reported
hat the hydrophilic polymers could improve the complexation
fﬁciency (CE) and the stability constants (K1:1) of cyclodextrin
nclusions for drugs [31]. In our study, slope values for DHA–HP-
-CD binary system and DHA–HP-ˇ-CD–lecithin ternary systems
ere 0.161, 0.160 (with the lecithin concentration of 0.5%, w/v)
nd 0.148 (with the lecithin concentration of 1.0%, w/v). The corre-
ponding CE values were 0.192, 0.190 and 0.174. The CE value might
ndicate the similar solubilizing efﬁciency of DHA–HP-ˇ-CD binary
ystem and DHA–HP-ˇ-CD–lecithin ternary system. The S0 (Eq. (3))
n the presence of 0.5% (w/v) lecithin and 1.0% (w/v) lecithin were
52.3 ± 2.6 g mL−1 and 538.9 ± 22.5 g mL−1. According to Eq. (3),
he corresponding K1:1 values were 415, 214 and 91 M−1. The K1:1
alue decreased from 415 M−1 for the DHA–HP-ˇ-CD binary sys-
em to 91 M−1 for the DHA–HP-ˇ-CD–lecithin ternary system (1.0%,
/v, lecithin), with an improvement of S0 in the present of lecithin.
 sharp reduction of the K1:1 value suggested that the addition
f lecithin might decrease the interaction between HP-ˇ-CD and
HA. The reduced afﬁnity for the HP-ˇ-CD cavity might due to the
nteraction between DHA and lecithin.
.3. Characterization of the binary systems and the ternary
ystem
For the preparation of binary and ternary systems, lecithin can
ardly be dissolved in water. Low molecular weight alcohols as
ethanol and ethanol were added as the solvent. Methanol was
hosen in consideration of its high drug loading. The drug load-
ng of DHA–HP-ˇ-CD binary system prepared with methanol and
thanol were 5.35% and 4.51%, respectively. This may  be attributed
o the stronger polarity of methanol and the tendency of DHA to be
ncapsulated by the hydrophobic cavity of HP-ˇ-CD in the strong
olarity of solvents [31]. The residual methanol in the ﬁnal products
as determined by gas chromatography (Agilent6890, Palo Alto,
SA). The residual methanol in the ﬁnal products was  2.15 ppm,
hich was much less than the limitation speciﬁed as 3000 ppm
n the European Pharmacopoeia (7th edition), indicating that the
ernary system was safe for the case of methanol impurity.
The drug loading of DHA–HP-ˇ-CD binary system, DHA–lecithin
inary system and the ternary system were 5.35% (DHA: HP-ˇ-CD,
:17, w/w), 5.28% (DHA: lecithin, 1:18, w/w) and 5.02% (DHA: HP-
-CD–lecithin, 1:19, w/w) respectively.ical mixture (D), DHA–HP-ˇ-CD binary system (E), DHA–lecithin physical mixture
(F), DHA–lecithin binary system (G), DHA–HP-ˇ-CD–lecithin physical mixture (H)
and DHA–HP-ˇ-CD–lecithin ternary system (I).
3.3.1. Fourier transform infrared spectroscopy
FT-IR spectra of pure DHA, HP-ˇ-CD, lecithin, and the two binary
systems, the ternary system were shown in Fig. 2. For the FT-
IR spectrum of pure DHA (Fig. 2A), sharp peaks at 3380 cm−1,
2800–3000 cm−1, 800–900 cm−1 could be considered as the main
characteristic peaks for the stretching vibrations of OH groups,
C H bond and C O bond (in the seven-membered ring) in DHA
[32,33]. Compared with DHA (Fig. 2A), the changes to these three
sharp characteristic peaks were observed in DHA–HP-ˇ-CD binary
system (Fig. 2E), DHA–lecithin binary system (Fig. 2G) and the
DHA–HP-ˇ-CD–lecithin ternary system (Fig. 2I). It indicated that
the host-guest interactions may  exist in these systems.
For the ternary system (Fig. 2I) and its corresponding physical
mixture (Fig. 2H), the former showed band shifting at 3384 cm−1
while the latter exhibited peaks at 3378 cm−1. Furthermore, the
ternary system showed smaller peaks of the C H stretching in the
range 2800–3000 cm−1 than that for DHA and the binary systems.
Additionally, the intensity of the C O peak for lecithin at 1753 cm−1
(Fig. 2C) greatly decreased in the ternary system (Fig. 2I) [34]. In
the ﬁngerprint region, the peaks of lecithin (Fig. 2C) at 1238 and
968 cm−1 could be assigned to the absorbance of P O and +N(CH3)3
stretching vibrations respectively [35]. These peaks were also found
in the ternary physical mixtures. While for the ternary system, the
P O peak shifted from 1238 to 1234 cm−1 and the peak at 968 cm−1
disappeared. It might indicate that host–guest interactions existed
and new solid phases formed in the ternary system compared with
its corresponding physical mixture.
3.3.2. Differential scanning calorimetry
The DSC thermogram of DHA showed typical characteristics of
a crystalline substance, exhibiting two  exothermic peaks at 155.03
and 170.08 ◦C which might be assigned as the melt of decompo-
sition of peroxide, while HP-ˇ-CD and lecithin did not show any
endothermic or exothermic peaks (Fig. 3).
The physical mixtures of the binary systems and the ternary sys-
tem also showed exothermic peaks (DHA–HP-ˇ-CD binary physical
mixture at 167.55 ◦C; DHA–lecithin binary physical mixture at
153.12 ◦C; ternary physical mixture at 157.25 ◦C). However, thetem and the ternary system, which might be ascribed to the new
amorphous solid formed or the molecular inclusion formed in the
binary system and the ternary system.
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Fig. 3. DSC thermograms of pure DHA (A), HP-ˇ-CD (B), lecithin (C), DHA–HP-ˇ-CD
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Chysical mixture (D), DHA–HP-ˇ-CD binary system (E), DHA–lecithin physical mix-
ure (F), DHA–lecithin binary system (G), DHA–HP-ˇ-CD–lecithin physical mixture
H)  and DHA–HP-ˇ-CD–lecithin ternary system (I).
.3.3. Powder X-ray diffraction
The PXRD patterns of DHA, lecithin, DHA–HP-ˇ-CD–lecithin
hysical mixture and the ternary system showed obvious differ-
nce. The peaks in the diffraction pattern of DHA powder were
harp and high with the main diffraction angles (2) at 7.7◦, 9.3◦ and
1.2◦, suggesting the signiﬁcant crystallinity of DHA. The lecithin
howed a ﬂat pattern as typical diffraction pattern of amorphous
ubstance. For the ternary physical mixture, lower intensities of the
rystalline diffraction peaks of DHA could be observed at 7.9◦, 9.5◦
nd 11.3◦, in which the typical peaks from DHA were presented and
o new peaks were observed, suggesting the absence of interaction
mong drug, HP-ˇ-CD and lecithin in their physical mixture. For the
ernary system, there was neither typical DHA diffraction peak at
–15◦ nor any new peaks, indicating the complete disappearance
f DHA crystallinity and new solid phase formed in the ternary sys-
em [32]. The result was consistent with the results obtained from
T-IR and DSC studies (Fig. 4).
.4. Property of the binary system and the ternary system in
queous state
.4.1. In vitro dissolution
Compared to the DHA powders, the dissolution proﬁles of the
inary system and the ternary system showed great improve-
ents of the cumulative release amounts and the release onsets
ig. 4. X-ray powder diffraction patterns of pure DHA (A), lecithin (C), DHA–HP-ˇ-
D–lecithin physical mixture (H) and DHA–HP-ˇ-CD–lecithin ternary system (I).Fig. 5. Dissolution curves of pure DHA  (), DHA–HP-ˇ-CD binary system (),
DHA–lecithin binary system (©) and DHA–HP-ˇ-CD–lecithin ternary system ()
at  37 ◦C. Error bars are s.d. (n = 3).
were in the order of DHA–HP-ˇ-CD binary system > DHA–HP-ˇ-
CD–lecithin ternary system > DHA–lecithin binary system > DHA.
The dissolution rates of DHA in the HP-ˇ-CD based binary and
ternary system were obviously faster than that in the DHA–lecithin
binary system and DHA. The dissolution percentages of DHA in the
HP-ˇ-CD based binary system and ternary system were larger than
90% at 120 min. In addition, the dissolution percentages of DHA
in its pure form and in the DHA–lecithin binary system were only
15.5 ± 0.9% and 62.2 ± 8.1% at 120 min  (Fig. 5).
The good dissolution performance for the DHA–HP-ˇ-CD binary
system and the ternary system might be attributed to the concur-
rence of several factors, e.g., the reduction of the DHA crystallinity in
these two systems, which were conﬁrmed by DSC and PXRD stud-
ies, and possibly increased particle wettability in the presence of
hydrophilic HP-ˇ-CD and lecithin.
3.4.2. Stability studies
3.4.2.1. Stability of DHA in aqueous solution. The concentration of
DHA in water was nearly unchanged within 6 h and 96% left at 37 ◦C.
Although DHA was stable in water in our experiment condition, it
was unstable in Hank’s balanced salt solutions (pH7.4). The degra-
dation of DHA in Hank’s balanced salt solutions (pH7.4) followed
ﬁrst order reaction described by Eq. (1) (R2 > 0.98). The degradation
rate constant values were calculated by linear regression of ln[C]
and t. The changes of DHA concentration percentage as a function
of time were shown in Fig. 6.
Fig. 6. The changes of DHA concentration percentage as a function of time in Hank’s
balanced salt solution (pH6.8 (), pH7.0 (), pH7.2 (), pH7.4 (©)) at 37 ◦C. Error
bars are s.d. (n = 3).
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Fig. 7. The changes of DHA concentration percentage as a function of time in Hank’s
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salanced salt solution (pH7.4) at 37 ◦C for DHA (), DHA–HP-ˇ-CD binary system
),  DHA–lecithin binary system (©)  and DHA–HP-ˇ-CD–lecithin ternary system
). Error bars are s.d. (n = 3).
The degradation rate constants of DHA at 37 ◦C in pH6.8, 7.0,
.2 and 7.4 Hank’s balanced salt solutions were 0.04 ± 0.006,
.09 ± 0.008, 0.18 ± 0.001 and 0.48 ± 0.035 h−1 respectively. With
he pH increasing, values of k tended to rise. At pH 7.4, there were
nly 14% percentages of DHA left in the Hank’s balanced salt solu-
ion at 4 h.
.4.2.2. Stability of binary and ternary system in aqueous solutions.
s shown in Section 3.4.2.1. Stability of DHA in aqueous solution”,
he stability of DHA in pH7.4 Hank’s balanced salt solution was
ery poor and only 14% of DHA was left at 4 h. Therefore, the pH7.4
ank’s balanced salt solution was chosen as the solvent for the
tability analysis of DHA in the binary system and the ternary sys-
em. The changes of DHA concentration percentage as a function
f time and the degradation rate constant values were shown in
igs. 7 and 8.
As shown in Fig. 8, the solution of the ternary system
as the most stable sample, with the lowest k value of
.13 h−1. The rank order of the k values was DHA–lecithin
inary system > DHA > DHA–HP-ˇ-CD binary system > ternary sys-
em. Apparently, the stability of DHA in Hank’s balanced salt
olution with pH 7.4 was signiﬁcantly improved by the ternary sys-
em, with the k value decreased from 0.48 to 0.13 h−1. While the k
alue of the DHA–HP-ˇ-CD binary system decreased from 0.48 to
.38 h−1.
Zhang et al. [11] had investigated the effect of HP-ˇ-CD on
he stability of DHA in water at 60 ◦C. The value of k for DHA
ig. 8. The apparent degradation rate constants of DHA in Hank’s balanced salt
olution (pH7.4) at 37 ◦C for binary and ternary system. Error bars are s.d. (n = 3).Fig. 9. The possible molecular mechanism of interactions among DHA, HP--CD and
lecithin.
decreased by 75% (from 0.001842 min−1 to 0.000461 min−1) with
the presence of HP-ˇ-CD (57 mM).  Compared with their study, the
concentration of HP-ˇ-CD in our ternary system was about 0.7 mM
and the k value decreased by 73%. Thus, the addition of lecithin had
markedly enhanced the stability of DHA and reduced the dose of
HP-ˇ-CD signiﬁcantly.
In summary, with the consideration of simultaneous enhance-
ment of DHA solubility and stability in aqueous solutions,
DHA–HP-ˇ-CD–lecithin ternary system had signiﬁcant advantages
over DHA–HP-ˇ-CD and DHA–lecithin binary systems. Such an
effect, which was greater than the simple sum of the effects due
to the individual components, might be ascribed to the possible
formation of a ternary complex. According to the amphiphilic sur-
factant properties of lecithin, it might be assumed that the lecithin
possibly interacted with DHA via the hydrophobic interactions and
with HP-ˇ-CD via hydrogen bonding. Simultaneously, DHA  was
encapsulated by the hydrophobic cavity of HP-ˇ-CD.
The possibility of the above assumption was further investigated
by molecular docking studies (Fig. 9). Based on the calculation of
molecular charges with Gaussian software (version 9), the molecu-
lar docking was carried out with AutoDock Vina [36]. The simulated
annealing and optimization of the obtained complex were per-
formed with the force ﬁeld of CHARMm by Discovery Studio
(Accelrys Inc.). As shown in Fig. 9, DHA was  included into the
hydrophobic cavity of HP-ˇ-CD via hydrogen bonding, formed by
the OH group of DHA and the O of HP-ˇ-CD. There was  also a
hydrogen bond between the OH group outside the cavity of HP-ˇ-
CD and the PO2− of the lecithin. The hydrophobic tails of lecithin
covered the top of the wide rim of HP-ˇ-CD, and surrounded around
the peroxide bridging of DHA.
Therefore, interactions among DHA, HP-ˇ-CD and lecithin
existed in the ternary system: (1) hydrophobic interactions
between DHA and HP-ˇ-CD; (2) hydrophobic interactions between
DHA and lecithin; (3) hydrogen bonding of lecithin with HP-ˇ-CD or
its complex. The molecular evidence for the ternary complexation
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ssumption might also implicate the mechanism for the simul-
aneous improvement of DHA solubility and stability in aqueous
olutions by the ternary system.
. Conclusions
In this study, the solubility and stability of DHA in aqueous solu-
ions were enhanced by ternary system of DHA with HP-ˇ-CD and
oybean lecithin. The solid state characterizations illustrated the
ormation of a new solid phase, indicating the formation of the
ernary system. In aqueous state, the solubility, dissolution and
he stability of DHA in ternary system were better than that in
he pure form and binary systems, which might be ascribed to the
ernary complexation. The ternary complexation assumption was
urther implicated with the aid of molecular docking studies. In
ummary, the ternary system prepared in our study, with simul-
aneous enhancement of DHA solubility and stability in aqueous
olutions, might have an important pharmaceutical potential in the
evelopment of a better oral formulation of DHA.
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